This is a double-blind, randomized, multiregion, comparative phase ? clinical studydesigned to evaluate the efficacy and safety of HLX22 in combination with trastuzumab andchemotherapy as first-line treatment in patients with HER2-positive locallyadvanced/metastatic adenocarcinoma of the gastric and/or gastroesophageal junction(G/GEJ).Eligible subjects will be randomized to the two groups based on a 1:1 ratio.Enrolled subjects shall be treated with the study drug until the loss of clinicalbenefit, death, intolerable toxicity, withdrawal of informed consent, or other reasonsspecified by the protocol (whichever occurs first).
This is a double-blind, randomized, multiregion, comparative phase ? clinical studydesigned to evaluate the efficacy and safety of HLX22 in combination with trastuzumab andchemotherapy as first-line treatment in patients with HER2-positive locallyadvanced/metastatic adenocarcinoma of the gastric and/or gastroesophageal junction(G/GEJ).Eligible subjects will be randomized to the two groups based on a 1:1 ratio.Enrolled subjects shall be treated with the study drug until the loss of clinicalbenefit, death, intolerable toxicity, withdrawal of informed consent, or other reasonsspecified by the protocol (whichever occurs first).
